Tirzepatide
Mounjaro Analog
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This 39-amino acid peptide represents a significant advancement in metabolic research, combining the actions of two incretin hormones. Our tirzepatide is synthesized using advanced SPPS technology with C18 fatty acid conjugation for extended half-life.
Key Benefits
Available Sizes
B2B Wholesale Only · For Research Use Only · COA Provided with Every Order
Product Description
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This 39-amino acid peptide represents a significant advancement in metabolic research, combining the actions of two incretin hormones. Our tirzepatide is synthesized using advanced SPPS technology with C18 fatty acid conjugation for extended half-life.
Amino Acid Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-NH₂
Molecular Information
Request a Wholesale Quote
Fill out the form and our B2B team will respond within 24 hours with pricing, MOQ, and availability for Tirzepatide.
Related Research
Peer-reviewed scientific literature on Tirzepatide from PubMed, NEJM, The Lancet, and other authoritative sources.
Research Use Only. The following citations are provided for informational purposes and represent independent scientific research. These studies do not constitute medical advice or claims about our products. All products are sold for research purposes only and are not intended for human use.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
New England Journal of Medicine, 387: 205–216 (2022)
Participants receiving tirzepatide 15 mg lost a mean of 20.9% of body weight vs. 3.1% with placebo (p<0.001). This represented the largest weight loss ever observed in a phase 3 obesity pharmacotherapy trial.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frias JP, Davies MJ, Rosenstock J, et al.
New England Journal of Medicine, 385: 503–515 (2021)
All tirzepatide doses showed superior HbA1c reductions compared to semaglutide 1 mg. Tirzepatide 15 mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide (p<0.001), with greater weight loss (−11.2 kg vs. −5.3 kg).
Dual GIP and GLP-1 Receptor Agonist Tirzepatide: A Review of Its Mechanism of Action
Min T, Bain SC.
Drugs, 81: 1905–1918 (2021)
The synergistic activation of both GIP and GLP-1 receptors by tirzepatide produces additive metabolic benefits beyond either pathway alone, explaining its superior efficacy compared to selective GLP-1 agonists.
Citations sourced from PubMed / NCBI, New England Journal of Medicine, The Lancet, Nature, and other peer-reviewed publications. DOI links lead to original publisher pages.
Related Products
Semaglutide
GLP-1 receptor agonist for metabolic research and weight management applications.
Retatrutide
Triple-agonist candidate for advanced metabolic regulation and adiposity research.
Cagrilintide
Long-acting amylin analog peptide used in appetite and obesity-related studies.